Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma Clinical Trials in Zhengzhou, Henan

A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma